-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
-
(2005)
CA Cancer J. Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
-
2
-
-
0032815641
-
Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer. Too good to be true?
-
Borner MM. Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer. Too good to be true? Ann. Oncol. 10, 623-626 (1999).
-
(1999)
Ann. Oncol
, vol.10
, pp. 623-626
-
-
Borner, M.M.1
-
3
-
-
0018761436
-
The clinical correlation of an autopsy study of recurrent colorectal cancer
-
Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann. Surg. 189, 496-502 (1979).
-
(1979)
Ann. Surg
, vol.189
, pp. 496-502
-
-
Welch, J.P.1
Donaldson, G.A.2
-
4
-
-
0033040354
-
Treatment of colorectal liver metastases
-
Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br. J. Surg. 86, 158-169 (1999).
-
(1999)
Br. J. Surg
, vol.86
, pp. 158-169
-
-
Geoghegan, J.G.1
Scheele, J.2
-
5
-
-
0034082744
-
Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized controlled trials
-
Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br. J. Cancer 82, 1789-1794 (2000).
-
(2000)
Br. J. Cancer
, vol.82
, pp. 1789-1794
-
-
Jonker, D.J.1
Maroun, J.A.2
Kocha, W.3
-
6
-
-
2142703727
-
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
-
Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22, 1209-1214 (2004).
-
(2004)
J. Clin. Oncol
, vol.22
, pp. 1209-1214
-
-
Grothey, A.1
Sargent, D.2
Goldberg, R.M.3
-
7
-
-
0038600610
-
Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases
-
Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol. 14(Suppl. 2), ii13-ii16 (2003).
-
(2003)
Ann. Oncol
, vol.14
, Issue.SUPPL. 2
-
-
Adam, R.1
-
8
-
-
0031052731
-
Liver resection for colorectal metastases
-
Fong Y, Cohen AM, Fortner JG et al. Liver resection for colorectal metastases. J. Clin. Oncol. 15, 938-946 (1997).
-
(1997)
J. Clin. Oncol
, vol.15
, pp. 938-946
-
-
Fong, Y.1
Cohen, A.M.2
Fortner, J.G.3
-
9
-
-
0032791959
-
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
-
Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol. 10, 663-669 (1999).
-
(1999)
Ann. Oncol
, vol.10
, pp. 663-669
-
-
Giacchetti, S.1
Itzhaki, M.2
Gruia, G.3
-
10
-
-
20944450851
-
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases
-
Pawlik TM, Scoggins CR, Zorzi D et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg. 241, 715-722 (2005).
-
(2005)
Ann. Surg
, vol.241
, pp. 715-722
-
-
Pawlik, T.M.1
Scoggins, C.R.2
Zorzi, D.3
-
11
-
-
0026006962
-
Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
-
Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 9, 1967-1972 (1991).
-
(1991)
J. Clin. Oncol
, vol.9
, pp. 1967-1972
-
-
Poon, M.A.1
O'Connell, M.J.2
Wieand, H.S.3
-
12
-
-
0024390441
-
Resection of hepatic metastases from colorectal cancer. Biologic perspective
-
Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann. Surg. 210, 127-138 (1989).
-
(1989)
Ann. Surg
, vol.210
, pp. 127-138
-
-
Steele Jr, G.1
Ravikumar, T.S.2
-
13
-
-
0025832661
-
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastro-intestinal Tumor Study Group Protocol 6584
-
Steele G Jr, Bleday R, Mayer RJ et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastro-intestinal Tumor Study Group Protocol 6584. J. Clin. Oncol. 9, 1105-1112 (1991).
-
(1991)
J. Clin. Oncol
, vol.9
, pp. 1105-1112
-
-
Steele Jr, G.1
Bleday, R.2
Mayer, R.J.3
-
15
-
-
0033014829
-
Factors influencing survival of patients undergoing hepatectomy for colorectal metastases
-
Yamamoto J, Shimada K, Kosuge T et al. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br. J. Surg. 86, 332-337 (1999).
-
(1999)
Br. J. Surg
, vol.86
, pp. 332-337
-
-
Yamamoto, J.1
Shimada, K.2
Kosuge, T.3
-
16
-
-
0036794139
-
Liver resection for multiple colorectal metastases: Influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival
-
Ercolani G, Grazi GL, Ravaioli M et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch. Surg. 137, 1187-1192 (2002).
-
(2002)
Arch. Surg
, vol.137
, pp. 1187-1192
-
-
Ercolani, G.1
Grazi, G.L.2
Ravaioli, M.3
-
17
-
-
0036104072
-
Trends in long-term survival following liver resection for hepatic colorectal metastases
-
Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg. 235, 759-766 (2002).
-
(2002)
Ann. Surg
, vol.235
, pp. 759-766
-
-
Choti, M.A.1
Sitzmann, J.V.2
Tiburi, M.F.3
-
18
-
-
7744241808
-
The clinical risk score: Emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases
-
Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch. Surg. 139, 1168-1172 (2004).
-
(2004)
Arch. Surg
, vol.139
, pp. 1168-1172
-
-
Mann, C.D.1
Metcalfe, M.S.2
Leopardi, L.N.3
Maddern, G.J.4
-
19
-
-
0037442149
-
Current treatment for liver metastases from colorectal cancer
-
Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J. Gastroenterol. 9, 193-200 (2003).
-
(2003)
World J. Gastroenterol
, vol.9
, pp. 193-200
-
-
Liu, L.X.1
Zhang, W.H.2
Jiang, H.C.3
-
20
-
-
0022516194
-
Determinants of survival in liver resection for colorectal secondaries
-
Ekberg H, Tranberg KG, Andersson R et al. Determinants of survival in liver resection for colorectal secondaries. Br. J. Surg. 73, 727-731 (1986).
-
(1986)
Br. J. Surg
, vol.73
, pp. 727-731
-
-
Ekberg, H.1
Tranberg, K.G.2
Andersson, R.3
-
21
-
-
39149102132
-
Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: A single-center experience
-
Nuzzo G, Giuliante F, Ardito F et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery 143, 384-393 (2008).
-
(2008)
Surgery
, vol.143
, pp. 384-393
-
-
Nuzzo, G.1
Giuliante, F.2
Ardito, F.3
-
22
-
-
0037273766
-
-
Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg. Oncol. Clin. N. Am. 12, 165-192, xi (2003).
-
Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg. Oncol. Clin. N. Am. 12, 165-192, xi (2003).
-
-
-
-
23
-
-
1542751128
-
The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies
-
Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann. Surg. Oncol. 10, 1007-1011 (2003).
-
(2003)
Ann. Surg. Oncol
, vol.10
, pp. 1007-1011
-
-
Jaeck, D.1
-
24
-
-
2942545920
-
Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis
-
Laurent C, Sa Cunha A, Rullier E et al. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J. Am. Coll. Surg. 198, 884-891 (2004).
-
(2004)
J. Am. Coll. Surg
, vol.198
, pp. 884-891
-
-
Laurent, C.1
Sa Cunha, A.2
Rullier, E.3
-
25
-
-
38849175589
-
Expanding criteria for resectability of colorectal liver metastases
-
Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 13, 51-64 (2008).
-
(2008)
Oncologist
, vol.13
, pp. 51-64
-
-
Pawlik, T.M.1
Schulick, R.D.2
Choti, M.A.3
-
26
-
-
66149155832
-
-
Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 20, 985-992 (2009). Expert panel recommendations for the treatment of metastatic colorectal cancer (CRC): the majority of patients with CRC liver metastases should be treated up front with chemotherapy, irrespective of the initial resectability status of their metastases.
-
Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 20, 985-992 (2009). Expert panel recommendations for the treatment of metastatic colorectal cancer (CRC): the majority of patients with CRC liver metastases should be treated up front with chemotherapy, irrespective of the initial resectability status of their metastases.
-
-
-
-
27
-
-
4344619216
-
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study
-
Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J. Clin. Oncol. 22, 3284-3292 (2004).
-
(2004)
J. Clin. Oncol
, vol.22
, pp. 3284-3292
-
-
Glehen, O.1
Kwiatkowski, F.2
Sugarbaker, P.H.3
-
28
-
-
59949086562
-
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin
-
Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J. Clin. Oncol. 27, 681-685 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 681-685
-
-
Elias, D.1
Lefevre, J.H.2
Chevalier, J.3
-
29
-
-
0029794696
-
Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
-
Pioneering retrospective study of the downstaging of colorectal metastases following combination chemotherapy
-
Bismuth H, Adam R, Lévi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224, 509-520 (1996). Pioneering retrospective study of the downstaging of colorectal metastases following combination chemotherapy.
-
(1996)
Ann. Surg
, vol.224
, pp. 509-520
-
-
Bismuth, H.1
Adam, R.2
Lévi, F.3
-
30
-
-
0035018397
-
Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal
-
Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol. 8, 347-353 (2001).
-
(2001)
Ann. Surg. Oncol
, vol.8
, pp. 347-353
-
-
Adam, R.1
Avisar, E.2
Ariche, A.3
-
31
-
-
0036889745
-
Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma
-
Rivoire M, De Cian F, Meeus P et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95, 2283-2292 (2002).
-
(2002)
Cancer
, vol.95
, pp. 2283-2292
-
-
Rivoire, M.1
De Cian, F.2
Meeus, P.3
-
32
-
-
33846073122
-
Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases
-
Baize N, Gerard B, Bleiberg H et al. Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol. Clin. Biol. 30, 1349-1353 (2006).
-
(2006)
Gastroenterol. Clin. Biol
, vol.30
, pp. 1349-1353
-
-
Baize, N.1
Gerard, B.2
Bleiberg, H.3
-
33
-
-
63449116518
-
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases
-
Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg. 249, 420-425 (2009).
-
(2009)
Ann. Surg
, vol.249
, pp. 420-425
-
-
Masi, G.1
Loupakis, F.2
Pollina, L.3
-
34
-
-
23844448040
-
Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates
-
Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16, 1311-1319 (2005).
-
(2005)
Ann. Oncol
, vol.16
, pp. 1311-1319
-
-
Folprecht, G.1
Grothey, A.2
Alberts, S.3
-
35
-
-
0035116969
-
Prospective Phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer
-
Gil-Delgado MA, Guinet F, Castaing D et al. Prospective Phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am. J. Clin. Oncol. 24, 101-105 (2001).
-
(2001)
Am. J. Clin. Oncol
, vol.24
, pp. 101-105
-
-
Gil-Delgado, M.A.1
Guinet, F.2
Castaing, D.3
-
36
-
-
0037256469
-
Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer
-
Wein A, Riedel C, Brückl W et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64, 131-138 (2003).
-
(2003)
Oncology
, vol.64
, pp. 131-138
-
-
Wein, A.1
Riedel, C.2
Brückl, W.3
-
37
-
-
10744229419
-
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)
-
Zelek L, Bugat R, Cherqui D et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann. Oncol. 14, 1537-1542 (2003).
-
(2003)
Ann. Oncol
, vol.14
, pp. 1537-1542
-
-
Zelek, L.1
Bugat, R.2
Cherqui, D.3
-
38
-
-
2642541197
-
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients
-
Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann. Oncol. 15, 933-939 (2004).
-
(2004)
Ann. Oncol
, vol.15
, pp. 933-939
-
-
Pozzo, C.1
Basso, M.2
Cassano, A.3
-
39
-
-
35348905517
-
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
-
Barone C, Nuzzo G, Cassano A et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br. J. Cancer 97, 1035-1039 (2007).
-
(2007)
Br. J. Cancer
, vol.97
, pp. 1035-1039
-
-
Barone, C.1
Nuzzo, G.2
Cassano, A.3
-
40
-
-
33644819672
-
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study
-
Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J. Clin. Oncol. 23, 9243-9249 (2005).
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 9243-9249
-
-
Alberts, S.R.1
Horvath, W.L.2
Sternfeld, W.C.3
-
41
-
-
33645269821
-
Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer
-
de la Cámara J, Rodriguez J, Rotellar F et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J. Clin. Oncol. 22(Suppl. 14), 3593 (2004).
-
(2004)
J. Clin. Oncol
, vol.22
, Issue.SUPPL. 14
, pp. 3593
-
-
de la Cámara, J.1
Rodriguez, J.2
Rotellar, F.3
-
42
-
-
2942638081
-
XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer
-
Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 22, 2084-2091 (2004).
-
(2004)
J. Clin. Oncol
, vol.22
, pp. 2084-2091
-
-
Cassidy, J.1
Tabernero, J.2
Twelves, C.3
-
43
-
-
20044365047
-
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: Results of a Phase II study
-
Taïeb J, Artru P, Paye F et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a Phase II study. J. Clin. Oncol. 23, 502-509 (2005).
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 502-509
-
-
Taïeb, J.1
Artru, P.2
Paye, F.3
-
44
-
-
43749090901
-
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A Phase II study in colorectal cancer patients with nonresectable liver metastases
-
Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a Phase II study in colorectal cancer patients with nonresectable liver metastases. Cancer Chemother. Pharmacol. 62, 195-201 (2008).
-
(2008)
Cancer Chemother. Pharmacol
, vol.62
, pp. 195-201
-
-
Ychou, M.1
Viret, F.2
Kramar, A.3
-
45
-
-
44149107591
-
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
-
Gruenberger B, Scheithauer W, Punzengruber R et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8, 120 (2008).
-
(2008)
BMC Cancer
, vol.8
, pp. 120
-
-
Gruenberger, B.1
Scheithauer, W.2
Punzengruber, R.3
-
46
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
Phase III clinical trial showing improved efficacy of oxaliplatin-based chemotherapy for the treatment of metastatic CRC
-
de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000). Phase III clinical trial showing improved efficacy of oxaliplatin-based chemotherapy for the treatment of metastatic CRC.
-
(2000)
J. Clin. Oncol
, vol.18
, pp. 2938-2947
-
-
de Gramont, A.1
Figer, A.2
Seymour, M.3
-
47
-
-
0034712536
-
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
-
Douillard J, Cunningham D, Roth A et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000).
-
(2000)
Lancet
, vol.355
, pp. 1041-1047
-
-
Douillard, J.1
Cunningham, D.2
Roth, A.3
-
48
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
-
(2000)
N. Engl. J. Med
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
49
-
-
17744418861
-
Randomized Phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
-
Köhne CH, Wils J, Lorenz M et al. Randomized Phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol. 21, 3721-3728 (2003).
-
(2003)
J. Clin. Oncol
, vol.21
, pp. 3721-3728
-
-
Köhne, C.H.1
Wils, J.2
Lorenz, M.3
-
50
-
-
1842569206
-
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
-
Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
-
(2004)
J. Clin. Oncol
, vol.22
, pp. 23-30
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
-
51
-
-
2542615200
-
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
-
André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343-2351 (2004).
-
(2004)
N. Engl. J. Med
, vol.350
, pp. 2343-2351
-
-
André, T.1
Boni, C.2
Mounedji-Boudiaf, L.3
-
52
-
-
20144389169
-
Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741
-
Delaunoit T, Alberts SR, Sargent DJ et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann. Oncol. 16, 425-429 (2005).
-
(2005)
Ann. Oncol
, vol.16
, pp. 425-429
-
-
Delaunoit, T.1
Alberts, S.R.2
Sargent, D.J.3
-
53
-
-
33644843853
-
OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study
-
Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J. Clin. Oncol. 24, 394-400 (2006).
-
(2006)
J. Clin. Oncol
, vol.24
, pp. 394-400
-
-
Tournigand, C.1
Cervantes, A.2
Figer, A.3
-
54
-
-
34249000361
-
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest
-
Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25, 1670-1676 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 1670-1676
-
-
Falcone, A.1
Ricci, S.2
Brunetti, I.3
-
55
-
-
36048960109
-
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study
-
Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol. 25, 4779-4786 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 4779-4786
-
-
Fuchs, C.S.1
Marshall, J.2
Mitchell, E.3
-
56
-
-
42949150908
-
Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
-
Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26, 2006-2012 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 2006-2012
-
-
Cassidy, J.1
Clarke, S.2
Díaz-Rubio, E.3
-
57
-
-
40749149728
-
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial
-
Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371, 1007-1016 (2008).
-
(2008)
Lancet
, vol.371
, pp. 1007-1016
-
-
Nordlinger, B.1
Sorbye, H.2
Glimelius, B.3
-
58
-
-
58549090953
-
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases
-
Scoggins CR, Campbell ML, Landry CS et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann. Surg. Oncol. 16, 35-41 (2009).
-
(2009)
Ann. Surg. Oncol
, vol.16
, pp. 35-41
-
-
Scoggins, C.R.1
Campbell, M.L.2
Landry, C.S.3
-
59
-
-
53049092394
-
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized Phase III noninferiority study
-
Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized Phase III noninferiority study. Ann. Oncol. 19, 1720-1726 (2008).
-
(2008)
Ann. Oncol
, vol.19
, pp. 1720-1726
-
-
Rothenberg, M.L.1
Cox, J.V.2
Butts, C.3
-
60
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized Phase II trial
-
Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. 23, 3697-7305 (2005).
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 3697-7305
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
-
61
-
-
33644697486
-
Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
-
Folprecht G, Lutz MP, Schöffski P et al. Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17, 450-456 (2006).
-
(2006)
Ann. Oncol
, vol.17
, pp. 450-456
-
-
Folprecht, G.1
Lutz, M.P.2
Schöffski, P.3
-
62
-
-
35648941728
-
Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
-
Saltz LB, Lenz HJ, Kindler HL et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25, 4557-4561 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 4557-4561
-
-
Saltz, L.B.1
Lenz, H.J.2
Kindler, H.L.3
-
63
-
-
36749067866
-
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
-
Tabernero J, Van Cutsem E, Díaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25, 5225-5232 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 5225-5232
-
-
Tabernero, J.1
Van Cutsem, E.2
Díaz-Rubio, E.3
-
64
-
-
49049105525
-
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study
-
Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol. 26, 3523-3529 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 3523-3529
-
-
Hochster, H.S.1
Hart, L.L.2
Ramanathan, R.K.3
-
65
-
-
42949130734
-
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
-
Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J. Clin. Oncol. 26, 1830-1835 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 1830-1835
-
-
Gruenberger, B.1
Tamandl, D.2
Schueller, J.3
-
66
-
-
46249096899
-
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: A randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK
-
Borner M, Koeberle D, Von Moos R et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann. Oncol. 19, 1288-1292 (2008).
-
(2008)
Ann. Oncol
, vol.19
, pp. 1288-1292
-
-
Borner, M.1
Koeberle, D.2
Von Moos, R.3
-
67
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663-671 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
68
-
-
73349122030
-
Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study)
-
Folprecht G, Gruenberger T, Hartmann JT et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). J. Clin. Oncol. 27, 296 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 296
-
-
Folprecht, G.1
Gruenberger, T.2
Hartmann, J.T.3
-
69
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Large Phase III clinical trial showing that the addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic CRC
-
Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). Large Phase III clinical trial showing that the addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic CRC.
-
(2004)
N. Engl. J. Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
70
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
71
-
-
63849088630
-
-
Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009). Large Phase III clinical trial of metastatic CRC showing that the benefit of cetuximab in combination therapy was limited to patients with KRAS wild-type tumors. Illustration of the use of biomarkers in patient selection.
-
Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009). Large Phase III clinical trial of metastatic CRC showing that the benefit of cetuximab in combination therapy was limited to patients with KRAS wild-type tumors. Illustration of the use of biomarkers in patient selection.
-
-
-
-
72
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized Phase III study
-
Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26, 2013-2019 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Díaz-Rubio, E.3
-
73
-
-
57349117528
-
Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
-
Cassidy J Cunningham D, Berry SR et al. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): first BEAT and NO16966. J. Clin. Oncol. 26(Suppl.), 4022 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.SUPPL.
, pp. 4022
-
-
Cassidy, J.1
Cunningham, D.2
Berry, S.R.3
-
74
-
-
66149120036
-
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study
-
Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20(11), 1842-1847 (2009).
-
(2009)
Ann. Oncol
, vol.20
, Issue.11
, pp. 1842-1847
-
-
Van Cutsem, E.1
Rivera, F.2
Berry, S.3
-
75
-
-
56749169353
-
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)
-
Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326-5334 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 5326-5334
-
-
Grothey, A.1
Sugrue, M.M.2
Purdie, D.M.3
-
76
-
-
44249111440
-
EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
-
Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2311-2319 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 2311-2319
-
-
Sobrero, A.F.1
Maurel, J.2
Fehrenbacher, L.3
-
77
-
-
59949102930
-
A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672-680 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 672-680
-
-
Hecht, J.R.1
Mitchell, E.2
Chidiac, T.3
-
78
-
-
59749091477
-
Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer
-
Combination biologic therapy with the addition of cetuximab to capecitabine, oxaliplatin and bevacizumab resulting in significantly shorter progression-free survival and inferior quality of life. Illustrates the problems currently facing clinicians with combination biologic therapy
-
Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009). Combination biologic therapy with the addition of cetuximab to capecitabine, oxaliplatin and bevacizumab resulting in significantly shorter progression-free survival and inferior quality of life. Illustrates the problems currently facing clinicians with combination biologic therapy.
-
(2009)
N. Engl. J. Med
, vol.360
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
-
79
-
-
69549147378
-
A Phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
-
Abstract LBA4
-
Wolmark N, Yothers G, O'Connell MJ et al. A Phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. 27(Suppl. 18), (2009) (Abstract LBA4).
-
(2009)
J. Clin. Oncol
, Issue.SUPPL. 18
, pp. 27
-
-
Wolmark, N.1
Yothers, G.2
O'Connell, M.J.3
-
80
-
-
65349189958
-
American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
-
Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 2091-2096
-
-
Allegra, C.J.1
Jessup, J.M.2
Somerfield, M.R.3
-
81
-
-
66849140563
-
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
-
Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 27, 2622-2629 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 2622-2629
-
-
Loupakis, F.1
Pollina, L.2
Stasi, I.3
-
82
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies
-
Sartore-Bianchi A, Martini M et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res. 69, 1851-1857 (2009).
-
(2009)
Cancer Res
, vol.69
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
Martini, M.2
-
83
-
-
68149165771
-
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
-
Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer 101, 465-472 (2009).
-
(2009)
Br. J. Cancer
, vol.101
, pp. 465-472
-
-
Souglakos, J.1
Philips, J.2
Wang, R.3
-
84
-
-
67649652208
-
BRAF mutation in metastatic colorectal cancer
-
Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98-99 (2009).
-
(2009)
N. Engl. J. Med
, vol.361
, pp. 98-99
-
-
Tol, J.1
Nagtegaal, I.D.2
Punt, C.J.3
-
85
-
-
34147103678
-
Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
-
van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 1658-1664
-
-
van Cutsem, E.1
Peeters, M.2
Siena, S.3
-
86
-
-
58949089717
-
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
-
New expert recommendations on the treatment of colorectal cancer in the elderly who are understaged, undertreated and underrepresented in clinical trials
-
Papamichael D, Audisio R, Horiot JC et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann. Oncol. 20, 5-16 (2009). New expert recommendations on the treatment of colorectal cancer in the elderly who are understaged, undertreated and underrepresented in clinical trials.
-
(2009)
Ann. Oncol
, vol.20
, pp. 5-16
-
-
Papamichael, D.1
Audisio, R.2
Horiot, J.C.3
|